Methods Fifty-two eyes of 33 consecutive patients were treated over a 6-month period.
The benefits of laser photocoagulation for the treatment of diabetic retinopathy have been well validated by two major multi-centre randomised prospective clinical trials: the Diabetic Retinopathy Study (DRS) and the Early Treatment of Diabetic Retinopathy Study (ETDRS). The primary effect of laser treatment is a thermal injury induced at the level of the retinal pigment epithelium (RPE), but concurrent damage to adjacent retinal conventional continuous wave (cw) laser systems cause damage to the neural retinal microstructures by thermal spread from the RPE -a clinically visible burn is taken as the threshold for treatment. It is not possible to isolate the injury to the RPE with cw laser exposure times (50-400 ms); this can only be attempted using much shorter laser exposure times of less than 1 ms which would confine the damage to the RPE / choroid melanin granules (Fig. 1) . It has been shown that laser pulses of extremely short duration affect the RPE alone with little effect on the photoreceptors or choriocapillaris from 'heat flow-away' or thermal spread from the primary irradiated area. This area of heat damage is called the thermal diffusion distance ? As the pulse duration is reduced the radius of the heat affected zone would also be reduced. Table 1 lists the thermal diffusion distance versus pulse duration in water, which is a good representation for ocular tissue. If the laser 'on' time is shorter than the thermal diffusion time (100 J-Ls) the distance between the RPE absorbing melanocytes and the photoreceptors (about 5-10 J-Lm from the RPE inner surface) is spared.
This concept of micropulse minimal impact photocoagulation can be achieved using the 810 nm infrared diode laser. Although dense cataract or significant vitreous haemorrhage reduces transmission of all wavelengths, the diode laser remains effective even when the ocular media are obscured (Table 2) . It is well absorbed by the RPE causing a more discrete temperature rise at the inner RPE surface. The diode laser can be electronically controlled to operate in the repetitive micropulse mode and this is a relatively easy technical event. 4 We wanted to evaluate whether the diode laser in micropulse mode was effective in the treatment of macular oedema secondary to branch retinal vein occlusion (BRVO) and diabetic maculopathy and in the treatment of proliferative diabetic retinopathy.
Methods
Patients attending the Medical Retina Service of Moorfields Eye Hospital over a 6-month period were recruited to the study. To be eligible, patients had to be willing and able to undergo fundus fluorescein angiography and be previously untreated for retinal vascular disorders (Table 3) .
All patients were treated by one observer (CM.M.) using the Iris Oculight SIx MicroPulse diode laser in micropulse mode with the 'on' time set at 100-300 fJ,S and the 'off' time set between 1900 and 1700 fJ,S repeatedly in a pulse envelope of 0.1-0.3 s duration. The power was initially adjusted upward to the minimum threshold value for a barely visible burn and then set at half that value during treatment. As the pigment in the RPE changed over the treatment area the visible threshold was checked occasionally.
The spot size used was between 200 and 500 fJ,m in diameter. Clinically significant macular oedema was treated with standard grid pattern photocoagulation to areas of retinal thickening; micro aneurysms were not specifically targeted. Patients were reviewed clinically and angiographically by two observers at 3 and 6 months and re-treated as necessary. No patient received more than three treatment episodes.
Proliferative diabetic retinopathy was treated with standard panretinal photocoagulation: 1500 burns initially, followed by a further 1500 burns at 6-week intervals depending on the clinical response. Patients
were assessed clinically at 3 and 6 months for complete, partial or no regression of new vessels. All patients were asked to grade the level of discomfort felt during treatment on a scale of 1-10, with 1
representing no sensation at all and 10 representing severe discomfort. We anticipated the following clinical effects:
1. The damage would be confined to the RPE. Nine patients were treated for proliferative diabetic retinopathy; 4 patients presented with bilateral disease. Overall the number of burns required to treat new vessels with the diode laser on micropulse mode was between 4500 and 6000 burns per eye (three or four treatment episodes). The average length of time required for patients to respond to treatment was 13 weeks. At 6 months 8 eyes (62%) of 5 patients showed complete regression of new vessels. A further 2 eyes (2 patients) showed partial regression. Both eyes were noted to have extensive ischaemic changes prior to treatment. One of these patients developed cardiac and renal problems during the study period and the other patient had poor glycaemic control throughout; both these factors may have affected the response to treatment. As they had persistent new vessels at the end of the study period they were further treated with argon laser panretinal photocoagulation. Their general medical problems were also being treated and at follow-up 3 months later the vessels had regressed. Three eyes (2 patients) showed minimal or no response to laser treatment over the 6-month study period. One patient had new vessels secondary to an ischaemic branch vein occlusion and did not attend regularly for treatment. He received a total of 3233 burns which may simply have been inadequate; he was eventually lost to follow-up. The other patient was a young obese woman with bilateral disease who was undergoing fertility treatment. She received 5668 burns to the left eye and 5500 to the right with minimal effect (Fig. 2) . In view of her age and lack of response by the end of the study period, she was treated with conventional argon panretinal photocoagulation to both eyes. The new vessels regressed after four treatment sessions and an additional 4500 burns to each eye.
Group 2: Macular oedema ( Table 5) Thirty-nine eyes of 33 patients were treated for macular oedema. Twenty-two eyes (57%) demonstrated resolution of macular oedema on angiography at 6 months (Fig. 3) . Fifteen eyes remained unchanged on angiography at the end of the study period and 2 eyes (1 patient) were worse. This last was an elderly patient with extensive long-standing macular oedema in both eyes. She had three treatment episodes without effect. Vision improved by 1 or more Snellen lines in 11 patients and was maintained in 27 (69%) patients.
One patient who had treatment for macular oedema returned at 3 months with a vitreous haemorrhage in the treated eye thought to be secondary to disc new vessels; he was removed from the study and treated with argon green panretinal photocoagulation.
There was no difference in response between patients with BRVO and diabetic macular oedema. Over half (54%) the eyes treated for macular oedema required more than one treatment episode (Table 6 ).
Clinical appearance of treated eyes
There was no visible burn at the time of treatment or immediately afterwards regardless of fundal pigmentation. This meant that the treating doctor had to plan in advance a treatment strategy for panretinal photocoagulation or risk either overtreating or undertreating certain areas. Treatment for eyes with macular oedema was performed with access to the fluorescein angiogram. At 3 months 8 (62%) eyes treated with panretinal photocoagulation had developed visible pigmented laser scars; all except 2 were heavily pigmented fundi. One- 
54% of patients required more than one treatment episode.
third (29%) of eyes treated for macular oedema had faint pigmentary disturbance at the level of the RPE at 3 months (Fig. 4) .
By 6 months 12 eyes (35%) showed no evidence of laser bums even on angiography; of these, 9 eyes had shown clinical and angiographic evidence of resolution of macular oedema.
Patient response to treatment
Treatment with the diode laser on micropulse mode was extremely well tolerated by all patients. None recorded any sensation during laser treatment (zero on the pain scale). This was especially relevant in patients undergoing panretinal photocoagulation. In addition, as there was no light flash, fixation was good and most patients were able to co-operate well during treatment of the macular region.
Discussion
The efficacy of both argon and diode laser photocoagulation in the treatment of diabetic maculopathy has been confirmed by the results of several studies. 5 -7 The precise mechanism of action of laser treatment in the resolution of macular oedema remains unclear. It is possible that changes in the microstructure of the retinal pigment epithelial cells result in increased removal of fluid from the retina. What is clear is that direct closure of retinal microaneurysms by heavy treatment with short-wave laser energy is not necessary We are currently recruiting patients to a randornised controlled study comparing the effects of conventional focal and panretinal argon green laser therapy with rnicropulsed diode laser treatment on visual fields and contrast sensitivity. Preliminary data suggest that the photoreceptor and inner retinal layers are preserved during treatment with the MicroPulse diode laser.
Conclusion
Patients tolerate treatment with the MicroPulse diode laser very well. It would appear that it is as efficient as the argon laser in the treatment of macular oedema and less disruptive; in many cases there was no visible evidence of treatment months later. Panretinal photocoagulation is also effective, with the majority of patients responding well. Further studies are needed to assess this effect in a larger group of patients. There were no complications or adverse effects noted in the patients treated with this form of laser.
